Concurrent enrollment on a non-chemotherapy treatment trial will be allowed, as long as that trial allows concurrent daily aspirin use
Concurrent enrollment in another clinical study, unless in follow-up period or it is an observational study
Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or the follow-up period of an interventional study;
Concurrent enrollment in another therapeutic clinical study. Enrollment in observational studies will be allowed
Concurrent hepatic veno-occlusive disease (VOD) based on clinical examination
Concurrent administration of other anti-cancer therapy during the course of this study is not allowed; note that concurrent use of supportive care medications (e.g. anti-resorptive agents, pain medications) is allowed
Concurrent administration of other cancer specific therapy during the course of this study is not allowed
Concurrent administration of other cancer specific therapy during the course of this study is not allowed
The subject must have completed RT with concurrent TMZ at least  weeks prior to the planned start of treatment on this study UNLESS there is pathological verification of recurrent tumor and at least  weeks have elapsed since the end of RT with concurrent TMZ.
Concurrent brain directed therapy (beyond SRS and NovoTTF-M as per protocol)
Concurrent enrollment in another interventional trial
Concurrent administration of other cancer specific therapy during the course of this study is not allowed
Eligible for otherwise curative treatment or undergoing concurrent therapy
Concurrent serious infection
Concurrent treatment with any chemotherapeutic agent
Patient must not have any active infection or concurrent illness obscuring toxicity or dangerously altering drug metabolism
Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study.
Concurrent brain-directed therapy
Concurrent enrollment in another study unless it is an observational (e.g. non-interventional) study.
Enrollment in a concurrent clinical study.
Concurrent treatment with non-permitted drugs and other interventions.
Concurrent radiation sensitizing medications concurrent with radiation, per treatment physician
Concurrent use of complementary or alternative medicines that would confound the interpretation of toxicities and antitumor activity of the study drugs
Male breast cancer patients. . Patients may not be on a concurrent clinical trial, unless approved by Investigator.
Concurrent participation in another clinical study that may add additional safety risks and/or confound study results*
Any known concurrent RAF or PIKCA mutation
Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study
Concurrent treatment with any chemotherapeutic agent.
Concurrent treatment with a non-permitted drug
Patients may not be on a concurrent clinical trial, unless approved by PI.
Concurrent treatment with any other anti-leukemia agent
Prior or concurrent treatment with AR antagonists or CYP enzyme inhibitor.
Concurrent treatment with a non-permitted drug
Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or the follow-up period of an interventional study
Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or the follow-up period of an interventional study, is excluded
Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or the follow-up period of an interventional study
Concurrent enrollment in another clinical trial, unless in a follow-up period or it is an observational study
Serious concurrent infection or nonmalignant illness that is uncontrolled or whose control may be jeopardized by complication of study therapy
Eligible for and planning to receive standard fractionated RT with concurrent TMZ
Concurrent use of systemic immune suppressive other than calcineurin inhibitors and sirolimus
Concurrent enrollment in another clinical study, unless in a follow-up period or the study is an observational or non-interventional study
Note: Concurrent and/or adjuvant chemotherapy does not make a patient ineligible; participation in a concurrent treatment protocol does not make a patient ineligible
Concurrent treatment with another anti-estrogen
Patient with any significant concurrent illness
PHASE II COLORECTAL CANCER COHORT  (MEDI+C ONLY):\r\nConcurrent enrollment in another clinical study, unless it is an observational non-interventional clinical study or the follow-up of an interventional study; any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment; concurrent use of hormones for non-cancer-related conditions (e.g., insulin for diabetes and hormone replacement therapy) is acceptable; NOTE: Local treatment of isolated lesions for palliative intent is acceptable (e.g., by local surgery or radiotherapy)
Concurrent use of bosentan
Concurrent administration of any other antitumor therapy.
Concurrent therapy with any drug active against simplexvirus (HSV) (acyclovir, valacyclovir, penciclovir, famcyclovir, gancyclovir, foscarnet, cidofovir)
The presence of a concurrent non-appendiceal metastatic cancer
Patient with concurrent use of complementary or alternative medicines
Concurrent serious infection
See Disease Characteristics PRIOR CONCURRENT THERAPY:
Previous or concurrent cancer except
Concurrent NSAID therapy; washout period of  days
Concurrent enrollment in another clinical study
Concurrent use of anticholinergics
Concurrent use of phenothiazine and atypical antipsychotics
Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study
Prior or concurrent use of trastuzumab
Any concurrent treatment that would compromise the study including but not limited to:
Concurrent somatostatin analogues are allowed provided that the dose has been stable (+/-  mg) for at least  weeks
Concurrent use of rifampin or ketoconazole
Concurrent enrollment in another clinical study, except for non-interventional, observational studies
Prior or concurrent use of erythropoietin is disallowed
Prior or concurrent topical or localized glucocorticosteroid therapy to treat non-malignant comorbid disorders is permitted
Plan to administer concurrent radiation therapy now or for progressive symptoms during treatment
Concurrent therapy given to treat cancer
Concurrent therapeutic intervention (including radiation therapy and NovoTTF).
Concurrent enrollment in another clinical study, unless it is an observational clinical study or the follow-up period of an interventional study
Concurrent treatment with a non permitted drug
Concurrent spironolactone use
No concurrent herbal or unconventional therapy
Concurrent hormone replacement therapy
Enrollment on any additional investigational agent study. Enrollment on concurrent observational study is allowed following consultation with the Sponsor.
Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) study.
Concurrent treatment with non-permitted drugs and other interventions
Concurrent or planned concurrent treatment with anticoagulants such as Coumadin or heparin, except to maintain patency of in dwelling catheters
Prior or concurrent therapy with somatostatin analogs is permitted for patients with secretory NET
Concurrent cancer therapy is not permitted.
Concurrent use of calcineurin-inhibitors plus sirolimus; either agent alone is acceptable
Participants with concurrent use of calcineurin-inhibitor plus sirolimus (either agent alone is acceptable)
Concurrent enrollment in another clinical study, unless it is an observational (non interventional) clinical study or the follow-up period of an interventional study
Concurrent treatment with any systemic chemotherapeutic agent
Concurrent use of complementary or alternative medicines that would confound the interpretation of toxicities and antitumor activity of the study drugs
Concurrent neurodegenerative disease,
Concurrent use of other antiandrogens, estrogen-like agents, or a-reductase inhibitors
Concurrent treatment with a non-permitted drug
Patients receiving any concurrent immunosuppressants
Participants receiving any other cancer directed concurrent therapy; such as concurrent chemotherapy, radiotherapy, or hormonal therapy; concurrent treatment with bisphosphonates/denosumab is allowed but should be started before starting treatment on study
Concurrent estrogens, anti-estrogens or progesterone compounds
Treatment plan to include delivery of concurrent chemoradiotherapy
Serious concurrent illness:
Patients in cohort  being treated with concurrent HER therapy must have undergone treatment with the concurrent HER therapy selected by their attending physician for at least  weeks prior to initiation on this study
Patients who are receiving any cancer-directed concurrent therapy, such as concurrent chemotherapy, radiotherapy, or hormonal therapy while on study; concurrent treatment with bisphosphonates and denosumab is allowed for bony metastases but should be started before the first dose of neratinib
Prior or concurrent exposure to approved or investigational multiple myeloma treatments (concurrent treatment with bone-protecting agents (eg, bisphosphonates, denosumab), or steroids (not exceeding  mg prednisone per day or equivalent) are only allowed if given in a stable dose and for a nonmalignant condition; concurrent treatment with erythropoietin-stimulating agents (ESAs) are not allowed.)
Patients must be registered on the study within  weeks of completion of concurrent chemoradiation
Concurrent treatment with a non-permitted drug.
Concurrent enrollment in another therapeutic investigational study or have previously taken ibrutinib
Subject must understand that while they are on study they cannot have any concurrent curative therapy for their cancer other than what is outlined in the protocol
Concurrent enrollment in another clinical study, unless in a follow-up period or it is an observational study
Concurrent neoplasia requiring cytotoxic therapy
Histopathological documentation of MCC concurrent with the diagnosis of metastatic disease
No concurrent cytochrome P A inducers
Concurrent therapy for cancer
Concurrent neoplasia requiring cytotoxic therapy
Concurrent radiation therapy, except for palliation of a single painful bone lesion or fracture.
Requirement for concurrent systemic glucocorticoid therapy at greater than physiologic replacement doses
Concurrent serious infection
Concurrent use of QT-prolonging medication
Concurrent treatment for cancer
No concurrent use of statins (except for pravastatin, if absolutely necessary)
Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or the follow-up period of an interventional study
Concurrent anticancer treatment with any agent other than iniparib and any co-administered chemotherapeutic agent(s) specified on the parental study protocol are not permitted throughout the course of the study.
Concurrent treatment with relevant doses of systemic glucocorticosteroids.
Significant concurrent disease.
Subjects who are considered to require concurrent therapy with another influenza antiviral medication.
Have a concurrent major debilitating illness,
Concurrent use of bupropion
Previous or concurrent use of flibanserin
Not have: concurrent use of ethyol; severe cognitive compromise; known history of central nervous system (CNS) disease (e.g. brain metastases, seizure disorder); concurrent use of amifostine, concurrent abdominal radiotherapy; concurrent use of quinolone antibiotic therapy; chronic alcoholism (as determined by the investigator); known hypersensitivity to olanzapine; known cardiac arrhythmia, uncontrolled congestive heart failure or acute myocardial infarction within the previous six months; history of uncontrolled diabetes mellitus (stable insulin dose and/or stable oral hypoglycemic agent permitted); or have planned chemotherapy or radiation during the  days following study initiation
Receiving concurrent radiation therapy
Concurrent use of somatostatin
Are receiving concurrent radiation therapy (RT)
Concurrent liposomal doxorubicin or any other liposomal agent
Concurrent breast related radiation therapy is allowed
BRAIN CANCER: Status post concurrent radiation therapy and daily temozolomide
Concurrent use of tamoxifen, raloxifene, or any of the aromatase inhibitors
Concurrent use of the aromatase inhibitor exemestane
Concurrent radiation, chemotherapeutic, or investigational therapy other than transplant related therapy
Concurrent enrollment in LCCC 
Concurrent antiandrogen therapy allowed but not required
Patients receiving concurrent additional biologic therapy
Concurrent use of calcineurin-inhibitor plus sirolimus (either agent alone is acceptable)
Current enrollment in any other trial that entails the concurrent administration of any other agent designed to enhance postoperative recovery
Concurrent hepatic veno-occlusive disease (VOD)
Concurrent diuretic use
Patients with evidence of concurrent adenocarcinoma-in-situ
Patients who have received a non-FDA or non-EMA approved anti-EGFR agent or any other non-FDA or non-EMA approved agent as part of concurrent radiotherapy
Concurrent therapy with other seizurogenic medications.
Completion of treatment with standard radiation (with or without concurrent therapy)
Concurrent therapy will be allowed
concurrent NSAID treatments while undergoing treatment
Concurrent disease or condition that interferes with participation or safety
